Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …

作者单位: 100021 北京, 中国医学科学院北京协和医学院肿瘤医院, 抗肿瘤分子靶向药物临床
研究北京市重点实验室(石远凯, 孙燕, 韩晓红, 郏博, 韩颖, 黄昱); 250117 济南 …

Background The role of gefitinib for the treatment of advanced non‐small cell lung cancer
(NSCLC) is evolving. We undertook a systematic review to evaluate the available evidence …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Background Neoadjuvant erlotinib and customized adjuvant therapy are appealing but
controversial. The purpose of this study was to evaluate the role of biomarker-guided …

Background Lung cancer is the leading cause of cancer-related deaths worldwide. Non-
small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti …

In the past decade, the standards of clinical trials in China have moved closer to
international standards, thus encouraging the development of innovative drugs. However, a …

Until recently, chemotherapy has remained the mainstay of treatment for the majority of
patients with advanced non-small cell lung cancer (NSCLC). Excellent responses have …

Introduction: Tumour molecular profiling has been at the crossroads of large-scale
integrative genomic studies and major clinical trials over the past 5 years and has provided …

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and
the treatment of advanced NSCLC relies on systemic treatments. During the last decade …